<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/EDC7316F-A897-4CBC-BA1F-30CE73C9FEFD"><gtr:id>EDC7316F-A897-4CBC-BA1F-30CE73C9FEFD</gtr:id><gtr:name>Astellas Pharma</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/6EC9A5B6-77FE-4FBD-9788-DE00A59CE4EB"><gtr:id>6EC9A5B6-77FE-4FBD-9788-DE00A59CE4EB</gtr:id><gtr:name>University Hospital Vall d'Hebron</gtr:name><gtr:address><gtr:line1>Passeig Vall d'Hebron</gtr:line1><gtr:line2>119-129</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/28DF10CD-6250-442A-804C-A8710CF218D1"><gtr:id>28DF10CD-6250-442A-804C-A8710CF218D1</gtr:id><gtr:name>University of Bern</gtr:name><gtr:address><gtr:line1>Universitat Bern</gtr:line1><gtr:line2>Sidlerstrasse 5</gtr:line2><gtr:line4>Bern</gtr:line4><gtr:line5>CH-3012</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/42B56A32-9194-468C-A790-BE55133838A6"><gtr:id>42B56A32-9194-468C-A790-BE55133838A6</gtr:id><gtr:name>University of Hamburg</gtr:name><gtr:address><gtr:line1>ZMK</gtr:line1><gtr:line2>Blunderstrasse</gtr:line2><gtr:line4>Hamburg</gtr:line4><gtr:line5>20146</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F7F8EA22-4A18-4B69-AA3D-A0E9C0B0EE7C"><gtr:id>F7F8EA22-4A18-4B69-AA3D-A0E9C0B0EE7C</gtr:id><gtr:name>ALTA</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/257C5108-1625-44DA-8C36-1FBC1CEF564E"><gtr:id>257C5108-1625-44DA-8C36-1FBC1CEF564E</gtr:id><gtr:name>King's College Hospital Charitable Trust</gtr:name><gtr:address><gtr:line1>King's College Hospital</gtr:line1><gtr:line2>Denamark Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE8 9RS</gtr:postCode><gtr:region>Unknown</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/88077807-2572-4B6D-8467-0822C6A212BD"><gtr:id>88077807-2572-4B6D-8467-0822C6A212BD</gtr:id><gtr:name>NHS Blood and Transplant (NHSBT)</gtr:name><gtr:address><gtr:line1>Oak House
Reeds Crescent</gtr:line1><gtr:city>Watford</gtr:city><gtr:postCode>WD24 4QN</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E20F47CA-8AB4-4F4D-A90D-A290834C65FF"><gtr:id>E20F47CA-8AB4-4F4D-A90D-A290834C65FF</gtr:id><gtr:name>University Hospital Coventry NHS Trust</gtr:name><gtr:address><gtr:line1>Clifford Bridge Road</gtr:line1><gtr:line2>Walsgrave</gtr:line2><gtr:postCode>CV2 2DX</gtr:postCode><gtr:region>Unknown</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/56443A66-B72D-4164-A2AE-F16898367510"><gtr:id>56443A66-B72D-4164-A2AE-F16898367510</gtr:id><gtr:name>Uppsala University</gtr:name><gtr:address><gtr:line1>PO Box 256</gtr:line1><gtr:postCode>SE-751 05</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E37A18E2-1E33-4ACE-BCFA-7DAD0DAF1261"><gtr:id>E37A18E2-1E33-4ACE-BCFA-7DAD0DAF1261</gtr:id><gtr:name>University of Regensburg</gtr:name><gtr:address><gtr:line1>University of Regensburg</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D1A0DAB7-FD0B-415C-A58B-F4CFC655E3FC"><gtr:id>D1A0DAB7-FD0B-415C-A58B-F4CFC655E3FC</gtr:id><gtr:name>Academic Medical Center (AMC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/337901E4-D9A7-438B-B275-0631F5F384A3"><gtr:id>337901E4-D9A7-438B-B275-0631F5F384A3</gtr:id><gtr:name>Royal Liverpool and Broadgreen University Hospital NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/60EC89C3-5A8E-40B6-8030-7D2502D8A36A"><gtr:id>60EC89C3-5A8E-40B6-8030-7D2502D8A36A</gtr:id><gtr:name>Epsom and St Helier University Hospitals NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/697A218B-22B0-4B35-AB67-06BF907EB2AB"><gtr:id>697A218B-22B0-4B35-AB67-06BF907EB2AB</gtr:id><gtr:name>BMI Healthcare</gtr:name><gtr:address><gtr:line1>4 Thameside Centre</gtr:line1><gtr:line2>Kew Bridge Road</gtr:line2><gtr:postCode>TW8 0HF</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E832F6A6-3277-4F25-9336-6E314913CB23"><gtr:id>E832F6A6-3277-4F25-9336-6E314913CB23</gtr:id><gtr:name>Hull and East Yorkshire Hospitals NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/6442075B-9FCD-4065-8EE0-56534DEAC1A5"><gtr:id>6442075B-9FCD-4065-8EE0-56534DEAC1A5</gtr:id><gtr:name>Genome Identification Diagnostics GmbH</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5E4F6BEA-8E66-490E-B61F-8CBB33116179"><gtr:id>5E4F6BEA-8E66-490E-B61F-8CBB33116179</gtr:id><gtr:name>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/EF46D1B5-9EE9-459F-8D6D-68C3987370BD"><gtr:id>EF46D1B5-9EE9-459F-8D6D-68C3987370BD</gtr:id><gtr:name>University Hospitals of Leicester NHS</gtr:name><gtr:address><gtr:line1>Leicester Royal Infirmary</gtr:line1><gtr:line2>Infirmary Square</gtr:line2><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 5WW</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5A8E328E-8A10-45F8-9C51-6BD66C215CC0"><gtr:id>5A8E328E-8A10-45F8-9C51-6BD66C215CC0</gtr:id><gtr:name>Nottingham University Hospital NHS Trust</gtr:name><gtr:address><gtr:line1>Nottingham University HospitalMedical Physics and clinical engineeringQMC Campus</gtr:line1><gtr:city>Nottingham</gtr:city><gtr:postCode>NG7 2UH</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/1B0161A9-9EC7-4A57-AC51-97057219C9DC"><gtr:id>1B0161A9-9EC7-4A57-AC51-97057219C9DC</gtr:id><gtr:name>Plymouth Hospitals NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D9E99D31-A5B6-43CF-83F5-20D97EBEC1D1"><gtr:id>D9E99D31-A5B6-43CF-83F5-20D97EBEC1D1</gtr:id><gtr:name>Cellogic GmbH</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D3D8A940-2BB9-4960-A5F6-1F54554C34FA"><gtr:id>D3D8A940-2BB9-4960-A5F6-1F54554C34FA</gtr:id><gtr:name>Portsmouth Hospitals NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5D6066EF-3116-4DB9-A313-EA86A562F928"><gtr:id>5D6066EF-3116-4DB9-A313-EA86A562F928</gtr:id><gtr:name>Imperial College Healthcare NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/AB000219-B681-4861-853A-EB9CDE05AEB3"><gtr:id>AB000219-B681-4861-853A-EB9CDE05AEB3</gtr:id><gtr:name>Belfast Health and Social Care Trust</gtr:name><gtr:address><gtr:line1>A Floor Belfast City Hospital
Lisburn Road</gtr:line1><gtr:city>Belfast</gtr:city><gtr:postCode>BT12 6BA</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2070F714-C13B-417D-B059-44B511471FF2"><gtr:id>2070F714-C13B-417D-B059-44B511471FF2</gtr:id><gtr:name>Institute for Clinical and Experimental Medicine (IKEM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DAEB2B76-3CE2-4F67-BE52-859227BD2B8F"><gtr:id>DAEB2B76-3CE2-4F67-BE52-859227BD2B8F</gtr:id><gtr:name>Great Ormond Street Hospital (GOSH)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3545CDC8-076D-4BD8-B370-8E558F9D46EE"><gtr:id>3545CDC8-076D-4BD8-B370-8E558F9D46EE</gtr:id><gtr:name>Leeds Teaching Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Beckett Street</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS9 7TF</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/0CAFBCA9-D47B-49C7-836E-E7F61BB6F4DE"><gtr:id>0CAFBCA9-D47B-49C7-836E-E7F61BB6F4DE</gtr:id><gtr:name>Nantes University Hospital - CHU Nantes</gtr:name><gtr:address><gtr:line1>5 allee de l'ile Gloriette</gtr:line1><gtr:postCode>44093</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5ABCC373-8D79-4794-9EAD-C1BAFAA2F5D7"><gtr:id>5ABCC373-8D79-4794-9EAD-C1BAFAA2F5D7</gtr:id><gtr:name>Milenia Biotec GmbH</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2C1C85FB-77AC-4019-9363-4A2E4A909E16"><gtr:id>2C1C85FB-77AC-4019-9363-4A2E4A909E16</gtr:id><gtr:name>Cardiff &amp; Vale University Health Board</gtr:name><gtr:address><gtr:line1>Heath Park</gtr:line1><gtr:line4>Cardiff</gtr:line4><gtr:postCode>CF14 4XW</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/BE7A2CDE-C041-4244-A92D-C4DC327E14B7"><gtr:id>BE7A2CDE-C041-4244-A92D-C4DC327E14B7</gtr:id><gtr:name>Cambridge University Hospitals</gtr:name><gtr:address><gtr:line1>Addenbrooke's Hospital
Hills Road</gtr:line1><gtr:city>Cambridge</gtr:city><gtr:postCode>CB2 0QQ</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/961A021E-606B-4E5B-A583-224BEFA3A5E8"><gtr:id>961A021E-606B-4E5B-A583-224BEFA3A5E8</gtr:id><gtr:name>Barts Health NHS Trust</gtr:name><gtr:address><gtr:line1>Barts Health NHS Trust</gtr:line1><gtr:line2>5th Floor, Aneurin Bevan House</gtr:line2><gtr:line3>81 Commercial Road</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>E1 1RD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/0792034E-7B08-4D03-A4E1-0F2F89D82900"><gtr:id>0792034E-7B08-4D03-A4E1-0F2F89D82900</gtr:id><gtr:name>Immunotech S.A.S.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9F7C81EF-E4F5-45C5-A902-F4CAB61D4A82"><gtr:id>9F7C81EF-E4F5-45C5-A902-F4CAB61D4A82</gtr:id><gtr:name>NHS Greater Glasgow and Clyde (NHSGGC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/BF056F42-5CA1-4C02-A8D3-AF6A9AA1A2FD"><gtr:id>BF056F42-5CA1-4C02-A8D3-AF6A9AA1A2FD</gtr:id><gtr:name>Salford Royal NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Cleveland House
Salford</gtr:line1><gtr:city>Greater Manchester</gtr:city><gtr:postCode>M6 8AL</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/19AE1042-BEA6-43F9-931B-07741962E417"><gtr:id>19AE1042-BEA6-43F9-931B-07741962E417</gtr:id><gtr:name>Central Manchester University Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9F389987-5CF8-4C31-B2E6-C5EE5CA19D4E"><gtr:id>9F389987-5CF8-4C31-B2E6-C5EE5CA19D4E</gtr:id><gtr:name>St George's Healthcare NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A"><gtr:id>9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A</gtr:id><gtr:name>Guy's and St Thomas' NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Westminster Bridge Road</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 7EH</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/46DB0EB7-3DE7-4E45-BFC0-2E7255E49A4B"><gtr:id>46DB0EB7-3DE7-4E45-BFC0-2E7255E49A4B</gtr:id><gtr:name>Bristol-Myers Squibb</gtr:name><gtr:address><gtr:line1>Bristol-Myers Squibb</gtr:line1><gtr:line2>311 Pennington Rocky Hill Road</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DAFB4671-B85C-4383-B20F-8699CB229939"><gtr:id>DAFB4671-B85C-4383-B20F-8699CB229939</gtr:id><gtr:name>Catalan Health Institute (ICS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/EDF9EB53-008B-4F75-A492-AC1ADCFE76F0"><gtr:id>EDF9EB53-008B-4F75-A492-AC1ADCFE76F0</gtr:id><gtr:name>Royal Free Hampstead NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/CB597297-71EC-49CA-868E-47371DFC4207"><gtr:id>CB597297-71EC-49CA-868E-47371DFC4207</gtr:id><gtr:name>Oxford Radcliffe Hospitals NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/37D03EDF-A585-4D7B-8E46-7A48F11DA5DC"><gtr:id>37D03EDF-A585-4D7B-8E46-7A48F11DA5DC</gtr:id><gtr:name>University Hospital Regensburg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2E8E7A84-3BC7-4739-986D-C05FC31789B8"><gtr:id>2E8E7A84-3BC7-4739-986D-C05FC31789B8</gtr:id><gtr:name>Charit? - University of Medicine Berlin</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A19A6372-A1A2-4F0D-AED7-7110E0A05C9B"><gtr:id>A19A6372-A1A2-4F0D-AED7-7110E0A05C9B</gtr:id><gtr:name>Sheffield Teaching Hospitals NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/6ED98605-E2D0-401D-A73F-A9923F6C5D9D"><gtr:id>6ED98605-E2D0-401D-A73F-A9923F6C5D9D</gtr:id><gtr:name>East Kent Hospitals University NHS Foundation Trust</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Immunology Infection and Inflam Diseases</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EDC7316F-A897-4CBC-BA1F-30CE73C9FEFD"><gtr:id>EDC7316F-A897-4CBC-BA1F-30CE73C9FEFD</gtr:id><gtr:name>Astellas Pharma</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/6EC9A5B6-77FE-4FBD-9788-DE00A59CE4EB"><gtr:id>6EC9A5B6-77FE-4FBD-9788-DE00A59CE4EB</gtr:id><gtr:name>University Hospital Vall d'Hebron</gtr:name><gtr:address><gtr:line1>Passeig Vall d'Hebron</gtr:line1><gtr:line2>119-129</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/28DF10CD-6250-442A-804C-A8710CF218D1"><gtr:id>28DF10CD-6250-442A-804C-A8710CF218D1</gtr:id><gtr:name>University of Bern</gtr:name><gtr:address><gtr:line1>Universitat Bern</gtr:line1><gtr:line2>Sidlerstrasse 5</gtr:line2><gtr:line4>Bern</gtr:line4><gtr:line5>CH-3012</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/42B56A32-9194-468C-A790-BE55133838A6"><gtr:id>42B56A32-9194-468C-A790-BE55133838A6</gtr:id><gtr:name>University of Hamburg</gtr:name><gtr:address><gtr:line1>ZMK</gtr:line1><gtr:line2>Blunderstrasse</gtr:line2><gtr:line4>Hamburg</gtr:line4><gtr:line5>20146</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F7F8EA22-4A18-4B69-AA3D-A0E9C0B0EE7C"><gtr:id>F7F8EA22-4A18-4B69-AA3D-A0E9C0B0EE7C</gtr:id><gtr:name>ALTA</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/257C5108-1625-44DA-8C36-1FBC1CEF564E"><gtr:id>257C5108-1625-44DA-8C36-1FBC1CEF564E</gtr:id><gtr:name>King's College Hospital Charitable Trust</gtr:name><gtr:address><gtr:line1>King's College Hospital</gtr:line1><gtr:line2>Denamark Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE8 9RS</gtr:postCode><gtr:region>Unknown</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/88077807-2572-4B6D-8467-0822C6A212BD"><gtr:id>88077807-2572-4B6D-8467-0822C6A212BD</gtr:id><gtr:name>NHS Blood and Transplant (NHSBT)</gtr:name><gtr:address><gtr:line1>Oak House
Reeds Crescent</gtr:line1><gtr:city>Watford</gtr:city><gtr:postCode>WD24 4QN</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E20F47CA-8AB4-4F4D-A90D-A290834C65FF"><gtr:id>E20F47CA-8AB4-4F4D-A90D-A290834C65FF</gtr:id><gtr:name>University Hospital Coventry NHS Trust</gtr:name><gtr:address><gtr:line1>Clifford Bridge Road</gtr:line1><gtr:line2>Walsgrave</gtr:line2><gtr:postCode>CV2 2DX</gtr:postCode><gtr:region>Unknown</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/56443A66-B72D-4164-A2AE-F16898367510"><gtr:id>56443A66-B72D-4164-A2AE-F16898367510</gtr:id><gtr:name>Uppsala University</gtr:name><gtr:address><gtr:line1>PO Box 256</gtr:line1><gtr:postCode>SE-751 05</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E37A18E2-1E33-4ACE-BCFA-7DAD0DAF1261"><gtr:id>E37A18E2-1E33-4ACE-BCFA-7DAD0DAF1261</gtr:id><gtr:name>University of Regensburg</gtr:name><gtr:address><gtr:line1>University of Regensburg</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1A0DAB7-FD0B-415C-A58B-F4CFC655E3FC"><gtr:id>D1A0DAB7-FD0B-415C-A58B-F4CFC655E3FC</gtr:id><gtr:name>Academic Medical Center (AMC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/337901E4-D9A7-438B-B275-0631F5F384A3"><gtr:id>337901E4-D9A7-438B-B275-0631F5F384A3</gtr:id><gtr:name>Royal Liverpool and Broadgreen University Hospital NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/60EC89C3-5A8E-40B6-8030-7D2502D8A36A"><gtr:id>60EC89C3-5A8E-40B6-8030-7D2502D8A36A</gtr:id><gtr:name>Epsom and St Helier University Hospitals NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/697A218B-22B0-4B35-AB67-06BF907EB2AB"><gtr:id>697A218B-22B0-4B35-AB67-06BF907EB2AB</gtr:id><gtr:name>BMI Healthcare</gtr:name><gtr:address><gtr:line1>4 Thameside Centre</gtr:line1><gtr:line2>Kew Bridge Road</gtr:line2><gtr:postCode>TW8 0HF</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E832F6A6-3277-4F25-9336-6E314913CB23"><gtr:id>E832F6A6-3277-4F25-9336-6E314913CB23</gtr:id><gtr:name>Hull and East Yorkshire Hospitals NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/6442075B-9FCD-4065-8EE0-56534DEAC1A5"><gtr:id>6442075B-9FCD-4065-8EE0-56534DEAC1A5</gtr:id><gtr:name>Genome Identification Diagnostics GmbH</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5E4F6BEA-8E66-490E-B61F-8CBB33116179"><gtr:id>5E4F6BEA-8E66-490E-B61F-8CBB33116179</gtr:id><gtr:name>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EF46D1B5-9EE9-459F-8D6D-68C3987370BD"><gtr:id>EF46D1B5-9EE9-459F-8D6D-68C3987370BD</gtr:id><gtr:name>University Hospitals of Leicester NHS</gtr:name><gtr:address><gtr:line1>Leicester Royal Infirmary</gtr:line1><gtr:line2>Infirmary Square</gtr:line2><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 5WW</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2400BE3D-876A-41C9-8178-94887A51CA1C"><gtr:id>2400BE3D-876A-41C9-8178-94887A51CA1C</gtr:id><gtr:name>University Hospitals Birmingham NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Metchley Park Road</gtr:line1><gtr:city>Birmingham</gtr:city><gtr:postCode>B15 2PR</gtr:postCode><gtr:region>West Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5A8E328E-8A10-45F8-9C51-6BD66C215CC0"><gtr:id>5A8E328E-8A10-45F8-9C51-6BD66C215CC0</gtr:id><gtr:name>Nottingham University Hospital NHS Trust</gtr:name><gtr:address><gtr:line1>Nottingham University HospitalMedical Physics and clinical engineeringQMC Campus</gtr:line1><gtr:city>Nottingham</gtr:city><gtr:postCode>NG7 2UH</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/1B0161A9-9EC7-4A57-AC51-97057219C9DC"><gtr:id>1B0161A9-9EC7-4A57-AC51-97057219C9DC</gtr:id><gtr:name>Plymouth Hospitals NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D9E99D31-A5B6-43CF-83F5-20D97EBEC1D1"><gtr:id>D9E99D31-A5B6-43CF-83F5-20D97EBEC1D1</gtr:id><gtr:name>Cellogic GmbH</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D3D8A940-2BB9-4960-A5F6-1F54554C34FA"><gtr:id>D3D8A940-2BB9-4960-A5F6-1F54554C34FA</gtr:id><gtr:name>Portsmouth Hospitals NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5D6066EF-3116-4DB9-A313-EA86A562F928"><gtr:id>5D6066EF-3116-4DB9-A313-EA86A562F928</gtr:id><gtr:name>Imperial College Healthcare NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AB000219-B681-4861-853A-EB9CDE05AEB3"><gtr:id>AB000219-B681-4861-853A-EB9CDE05AEB3</gtr:id><gtr:name>Belfast Health and Social Care Trust</gtr:name><gtr:address><gtr:line1>A Floor Belfast City Hospital
Lisburn Road</gtr:line1><gtr:city>Belfast</gtr:city><gtr:postCode>BT12 6BA</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2070F714-C13B-417D-B059-44B511471FF2"><gtr:id>2070F714-C13B-417D-B059-44B511471FF2</gtr:id><gtr:name>Institute for Clinical and Experimental Medicine (IKEM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DAEB2B76-3CE2-4F67-BE52-859227BD2B8F"><gtr:id>DAEB2B76-3CE2-4F67-BE52-859227BD2B8F</gtr:id><gtr:name>Great Ormond Street Hospital (GOSH)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3545CDC8-076D-4BD8-B370-8E558F9D46EE"><gtr:id>3545CDC8-076D-4BD8-B370-8E558F9D46EE</gtr:id><gtr:name>Leeds Teaching Hospitals NHS Trust</gtr:name><gtr:address><gtr:line1>Beckett Street</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS9 7TF</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/0CAFBCA9-D47B-49C7-836E-E7F61BB6F4DE"><gtr:id>0CAFBCA9-D47B-49C7-836E-E7F61BB6F4DE</gtr:id><gtr:name>Nantes University Hospital - CHU Nantes</gtr:name><gtr:address><gtr:line1>5 allee de l'ile Gloriette</gtr:line1><gtr:postCode>44093</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5ABCC373-8D79-4794-9EAD-C1BAFAA2F5D7"><gtr:id>5ABCC373-8D79-4794-9EAD-C1BAFAA2F5D7</gtr:id><gtr:name>Milenia Biotec GmbH</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2C1C85FB-77AC-4019-9363-4A2E4A909E16"><gtr:id>2C1C85FB-77AC-4019-9363-4A2E4A909E16</gtr:id><gtr:name>Cardiff &amp; Vale University Health Board</gtr:name><gtr:address><gtr:line1>Heath Park</gtr:line1><gtr:line4>Cardiff</gtr:line4><gtr:postCode>CF14 4XW</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/BE7A2CDE-C041-4244-A92D-C4DC327E14B7"><gtr:id>BE7A2CDE-C041-4244-A92D-C4DC327E14B7</gtr:id><gtr:name>Cambridge University Hospitals</gtr:name><gtr:address><gtr:line1>Addenbrooke's Hospital
Hills Road</gtr:line1><gtr:city>Cambridge</gtr:city><gtr:postCode>CB2 0QQ</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/961A021E-606B-4E5B-A583-224BEFA3A5E8"><gtr:id>961A021E-606B-4E5B-A583-224BEFA3A5E8</gtr:id><gtr:name>Barts Health NHS Trust</gtr:name><gtr:address><gtr:line1>Barts Health NHS Trust</gtr:line1><gtr:line2>5th Floor, Aneurin Bevan House</gtr:line2><gtr:line3>81 Commercial Road</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>E1 1RD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/0792034E-7B08-4D03-A4E1-0F2F89D82900"><gtr:id>0792034E-7B08-4D03-A4E1-0F2F89D82900</gtr:id><gtr:name>Immunotech S.A.S.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9F7C81EF-E4F5-45C5-A902-F4CAB61D4A82"><gtr:id>9F7C81EF-E4F5-45C5-A902-F4CAB61D4A82</gtr:id><gtr:name>NHS Greater Glasgow and Clyde (NHSGGC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/BF056F42-5CA1-4C02-A8D3-AF6A9AA1A2FD"><gtr:id>BF056F42-5CA1-4C02-A8D3-AF6A9AA1A2FD</gtr:id><gtr:name>Salford Royal NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Cleveland House
Salford</gtr:line1><gtr:city>Greater Manchester</gtr:city><gtr:postCode>M6 8AL</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/19AE1042-BEA6-43F9-931B-07741962E417"><gtr:id>19AE1042-BEA6-43F9-931B-07741962E417</gtr:id><gtr:name>Central Manchester University Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9F389987-5CF8-4C31-B2E6-C5EE5CA19D4E"><gtr:id>9F389987-5CF8-4C31-B2E6-C5EE5CA19D4E</gtr:id><gtr:name>St George's Healthcare NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A"><gtr:id>9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A</gtr:id><gtr:name>Guy's and St Thomas' NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Westminster Bridge Road</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 7EH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/46DB0EB7-3DE7-4E45-BFC0-2E7255E49A4B"><gtr:id>46DB0EB7-3DE7-4E45-BFC0-2E7255E49A4B</gtr:id><gtr:name>Bristol-Myers Squibb</gtr:name><gtr:address><gtr:line1>Bristol-Myers Squibb</gtr:line1><gtr:line2>311 Pennington Rocky Hill Road</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DAFB4671-B85C-4383-B20F-8699CB229939"><gtr:id>DAFB4671-B85C-4383-B20F-8699CB229939</gtr:id><gtr:name>Catalan Health Institute (ICS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EDF9EB53-008B-4F75-A492-AC1ADCFE76F0"><gtr:id>EDF9EB53-008B-4F75-A492-AC1ADCFE76F0</gtr:id><gtr:name>Royal Free Hampstead NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/CB597297-71EC-49CA-868E-47371DFC4207"><gtr:id>CB597297-71EC-49CA-868E-47371DFC4207</gtr:id><gtr:name>Oxford Radcliffe Hospitals NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/37D03EDF-A585-4D7B-8E46-7A48F11DA5DC"><gtr:id>37D03EDF-A585-4D7B-8E46-7A48F11DA5DC</gtr:id><gtr:name>University Hospital Regensburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2E8E7A84-3BC7-4739-986D-C05FC31789B8"><gtr:id>2E8E7A84-3BC7-4739-986D-C05FC31789B8</gtr:id><gtr:name>Charit? - University of Medicine Berlin</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A19A6372-A1A2-4F0D-AED7-7110E0A05C9B"><gtr:id>A19A6372-A1A2-4F0D-AED7-7110E0A05C9B</gtr:id><gtr:name>Sheffield Teaching Hospitals NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/6ED98605-E2D0-401D-A73F-A9923F6C5D9D"><gtr:id>6ED98605-E2D0-401D-A73F-A9923F6C5D9D</gtr:id><gtr:name>East Kent Hospitals University NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B03ADD5E-C8E4-44FE-8B6C-314D20BCB374"><gtr:id>B03ADD5E-C8E4-44FE-8B6C-314D20BCB374</gtr:id><gtr:firstName>Laurence</gtr:firstName><gtr:surname>Turka</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A2CBFAB6-FB6C-4828-B8DB-26B979CAB80A"><gtr:id>A2CBFAB6-FB6C-4828-B8DB-26B979CAB80A</gtr:id><gtr:firstName>Maria Puerto</gtr:firstName><gtr:surname>Hernandez-Fuentes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/38D3D2F5-1B35-4CA4-AA50-69967F931069"><gtr:id>38D3D2F5-1B35-4CA4-AA50-69967F931069</gtr:id><gtr:firstName>Graham</gtr:firstName><gtr:otherNames>Michael</gtr:otherNames><gtr:surname>Lord</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D755320B-897A-4664-984C-1480D6978A96"><gtr:id>D755320B-897A-4664-984C-1480D6978A96</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:surname>Lechler</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E4CD9B66-7C1E-49FE-9D9A-94847B8454FC"><gtr:id>E4CD9B66-7C1E-49FE-9D9A-94847B8454FC</gtr:id><gtr:firstName>Vicki</gtr:firstName><gtr:surname>Seyfert-Margolis</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0801537"><gtr:id>D4BD0ABE-9C8E-4DFB-951D-A9C6C9D06027</gtr:id><gtr:title>Biomarkers of clinical transplantation tolerance</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801537</gtr:grantReference><gtr:abstractText>Kidney transplant recipients need to be treated with drugs that hold down the immune system (immunosuppression) for life. These drugs have important side effects and we currently don?t have means to know how much treatment each patient needs.

We have recently defined a series of tests that may allow us to identify which kidney transplant recipients do not reject their grafts when taken off immunosuppression. These are very preliminary results. We need to perform several studies to confirm them. 

Thus, we are proposing to repeat the study in new groups of patients. If validated our tests could be used to safely minimise or remove immunosuppression in those kidney transplant recipients that don?t need it.</gtr:abstractText><gtr:technicalSummary>Studying a cohort of extremely rare but very informative tolerant kidney transplant recipients we have recently defined a set of biomarkers that can identify them with specificity of 0.964 and sensitivity of 0.933. Using molecular profiling, flow cytometry and IFNgamma; ELISpots we identify patients who have been weaned off all immunosuppression for longer than 1 year and whose kidney function has remained stable. A similar set of biomarkers (B cell expansion and molecular expression) was found by the Immune Tolerance Network (USA) on a similar group of patients. 

To translate these tolerance biomarker sets into clinically-useful tools, we propose to test if they are predictive of the tolerant state and if their expression is stable with time. We will do this in collaboration with the US based researchers to achieve a common tolerant biomarker set.
? Hypotheses to test:
 ? More than 80% of the newly recruited tolerant kidney transplant recipients are positive for the common tolerant biomarker set, compared to less than 20% in control groups. 
 ? Stability of the set of biomarkers of tolerance is maintained in more than 90% of the tolerant patients as long as their function remains stable.
 ? The expanded B cell numbers detected in both studies reflect an expansion of regulatory B cells in peripheral blood from tolerant kidney transplant recipients.

Methods: An observational cross-sectional study in 3 groups of patients:
? Patient groups:
 1.- New set of tolerant kidney transplant recipients from the US and Europe. Control groups: healthy controls, stable patients on triple therapy, stable patients on steroid monotherapy, patients with immunologically driven chronic allograft nephropathy and patients with psoriasis in remission.
 2.- All tolerant kidney transplant recipients previously studied to test stability of the signature.
 3.- Long term kidney transplant recipients with stable function and patients matched for time post-transplantation with deteriorating function in the last 12 months.

Measurements
? Primary outcome: frequency of patients that display the composite set of biomarkers of tolerance.
? Secondary Outcomes: Patient, graft survival, and biopsy proven acute rejection, independently and as a composite variable, graft function (eGFR, CRT), infection rate, cancer rate, major CV events. To compare between patients positive and negative for the biomarkers of tolerance.

Validation of the common tolerant biomarker set will mean that it could be used as a surrogate end point in clinical trials of transplantation tolerance; this will have substantial implications for the management of transplant patients.</gtr:technicalSummary><gtr:fund><gtr:end>2013-02-14</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-07-15</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1134839</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Portsmouth Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>AC8E70A4-B467-4BD0-B65B-446925FCA4AE</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>East Kent Hospitals University NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT consortium</gtr:description><gtr:id>B3908CEA-9582-4B8B-A638-10ABFE54AB7D</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bern</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>GAMBIT consortium</gtr:description><gtr:id>4FCB50B8-0933-4216-BD67-E82789B28B94</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>NHS Greater Glasgow and Clyde (NHSGGC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>0903A349-E026-4199-AA1A-CA80900CC2A9</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Central Manchester University Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>0F18C838-2CAE-4F6F-84B0-E496B999F775</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Free Hampstead NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT consortium</gtr:description><gtr:id>ECA141E4-96FB-4EE4-9EEF-3C8ACFB3BE6E</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leeds Teaching Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT consortium</gtr:description><gtr:id>8A17C995-6261-4B5D-8818-FDC5008873CD</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sheffield Teaching Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT consortium</gtr:description><gtr:id>A61BB513-052A-4475-B8AA-115214027818</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leeds Teaching Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>283A0DCC-6104-43DE-ADBD-6E62E28FD423</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Barts Health NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>73F69C0B-64C4-423C-A267-E5F8AA0EE74D</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Free Hampstead NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>59A0C51F-CD4D-4E2A-AAD0-D051613F6A30</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital Universitari Vall d'Hebron</gtr:collaboratingOrganisation><gtr:country>Israel, State of</gtr:country><gtr:department>Renal Unit</gtr:department><gtr:description>GAMBIT consortium</gtr:description><gtr:id>70CF24B2-5748-4D8D-B3EB-327B2A49FD39</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>BMI Healthcare</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>The Beaumont Hospital</gtr:department><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>E6263DF1-0178-49B1-BEFC-6A256139B858</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>5A45CD3C-67D7-43AF-8A55-B4E1968E19DD</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ
transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guy's and St Thomas' NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>DBCBE777-1CD6-41CF-84E5-7CB2AB2420FE</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cellogic GmbH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>36EEDE7A-D949-4E64-B05A-23AFBB8B1786</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ
transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sheffield Teaching Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>285362B8-26F9-4154-8E45-D27F695D5C1D</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Astellas Pharma</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>7588EB47-5183-482F-A4D2-E9F835BCB04D</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ
transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Milenia Biotec GmbH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>9B446C8A-BA5B-4DBF-8122-7FAD97161152</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ
transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>92A11E4A-5FEA-4200-A321-300CC3D7EBA9</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>9AB4F512-D432-418A-9F4E-7939A7590902</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ
transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Salford Royal NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT consortium</gtr:description><gtr:id>9A02AA24-D07B-4D14-B96D-6DDA94B9B867</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>0B9C0F82-A6A9-4FCF-8C63-47AF06F1A413</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT consortium</gtr:description><gtr:id>540AA85A-A60C-4005-8F64-278C2A6B3759</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oxford Radcliffe Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>D30FB351-D3F9-4685-99A7-1148BED0AF52</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Coventry and Warwickshire NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>9348931A-6FAC-4C01-8E01-C45A3AA5964E</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>NHS Greater Glasgow and Clyde (NHSGGC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT consortium</gtr:description><gtr:id>4A008F70-1CDB-46B2-9387-F0988787631C</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Birmingham NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>074627B3-C41C-44BD-9A79-583B8DEF2134</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Academic Medical Center (AMC)</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>08751930-55E3-49FE-B6D3-F8B9F793258E</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ
transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Nottingham University Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>96040250-70F5-4619-A5B5-B8802573C4E6</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Genome Identification Diagnostics GmbH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>D82E474E-AF19-44BC-9894-B98A8596EABB</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ
transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ALTA</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Research and Development in Biotechnology</gtr:department><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>347779F6-688C-4B29-B8C6-13BFC8F0031B</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ
transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Belfast Health and Social Care Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>F3CA39D8-F230-4AA8-BEB6-F735EF9E38E3</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Regensburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>EA92C834-9553-4A68-A57B-1ABE179D4EDB</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ
transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Portsmouth Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT consortium</gtr:description><gtr:id>0D90BF78-ED81-4A2A-9E42-E5580618D84E</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff and Vale University Health Board (Bwrdd Iechyd Prifysgol Caerdydd a'r Fro)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT consortium</gtr:description><gtr:id>4C8BD23F-0978-4DAB-86BE-14B6B4393575</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff and Vale University Health Board (Bwrdd Iechyd Prifysgol Caerdydd a'r Fro)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>DE1F5C47-B41E-4BC0-A84C-1E7443A6219B</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Immunotech S.A.S.</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>B5589B47-438F-45EC-941C-B74FBE8B9F14</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ
transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals of Leicester NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>01D191C8-4B9A-422C-832B-22819FCEFAEE</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guy's and St Thomas' NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Evelina London Children's Hospital</gtr:department><gtr:description>GAMBIT consortium</gtr:description><gtr:id>B1C5A683-7F84-4089-BA4F-42B81251D7A6</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>01FE8B6D-3F65-4B69-AEA1-97D4B765DF00</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>4214C411-A61C-4E00-8A06-421B68C2DF13</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Catalan Health Institute (ICS)</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:department>University Hospital of Bellvitge (HUB)</gtr:department><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>C0EC429D-6F36-4AC5-BE24-AC10395F30E8</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ
transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guy's and St Thomas' NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Transplant Unit</gtr:department><gtr:description>GAMBIT consortium</gtr:description><gtr:id>B68E35E4-4C68-44DD-A8B8-ADC2CCC6C881</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital of Nantes</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>A2C8605D-5458-4B8D-8034-90CF822D73CD</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ
transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>NHS Blood and Transplant (NHSBT)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>8C4EB29E-35EC-4095-A4E1-C9A3FA9C83BD</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Central Manchester University Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT consortium</gtr:description><gtr:id>8A9F47F1-0D82-476C-B77F-6D29033C533D</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Epsom and St Helier University Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>0C9E9EB2-D9D7-4329-B90C-44C81569AD94</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Uppsala (Uppsala universitet)</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>University Hospital</gtr:department><gtr:description>GAMBIT consortium</gtr:description><gtr:id>86A3AE8B-30B1-48FE-937D-E9E7E4F7A093</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Plymouth Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>C6171BBA-DBF8-4727-9878-22947777CE80</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bristol-Myers Squibb</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>F37AD300-8DC7-441C-88E2-3C08B67EC06F</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ
transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute for Clinical and Experimental Medicine (IKEM)</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:description>GAMBIT consortium</gtr:description><gtr:id>AB831588-157D-423A-A056-8B005AA5CE3A</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Charit? - University of Medicine Berlin</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>1AD6014D-5D6A-49B9-8068-636FE85758CB</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ
transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>University Court</gtr:department><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>62CAC7F2-E764-47A3-BB79-09803D607439</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Great Ormond Street Hospital (GOSH)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT consortium</gtr:description><gtr:id>8B804811-A193-4CFF-8395-2F9942C7695F</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals of Leicester NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT consortium</gtr:description><gtr:id>972535AD-344D-42EC-AADC-60590C390DEF</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital Regensburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>The ONE study - FP7 Consortium</gtr:description><gtr:id>E008612B-7603-499B-B457-8692B585278E</gtr:id><gtr:impact>Few manuscripts submitted.</gtr:impact><gtr:partnerContribution>Use of different cell type with the aim to induce tolerance in renal transplant patients.</gtr:partnerContribution><gtr:piContribution>Use of regulatory Tregs for the induction of tolerance in renal transplant patients.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>E192E50F-480D-46EB-9C26-729B28EBCFF5</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Liverpool and Broadgreen University Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>25FBFF6F-8347-41D6-8DEA-C2C086772FFC</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cambridge University Hospitals NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK and Ireland Renal Transplant Consortium (UKIRTC)</gtr:description><gtr:id>FE884DA9-E376-4375-B6FE-3B7F6D69ACE5</gtr:id><gtr:impact>Transplantomics III; conference where we had 3 invited speakers from the consortium. http://www.transplantomics.org/index.php?option=com_content&amp;amp;view=article&amp;amp;id=26&amp;amp;Itemid=140 
 
Publications:
1. Okada Y, et al Nat Genet. 2012. PMID: 22797727 
2. Wain LV, et al; Nat Genet. 2011 PMID: 21909110 
3. International Consortium for Blood Pressure Genome-Wide Association Studies, et al Nature. 2011 PMID: 21909115

Conference communication in British Transplantation Society, March 2013. Bornemouth, UK</gtr:impact><gtr:partnerContribution>Sample collection
Data collection
Sanger: performed chips and analysis of data, significant input in publication
consortium ideas for developments</gtr:partnerContribution><gtr:piContribution>Project Lead
Management
Contract of workers
Coordination of samples
Driving analysis
Funding
Driving publication</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Hamburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>39CA8D5D-9287-4EC4-829F-476426C3A48A</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ
transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College Hospital NHS Foundation Trust (NCH)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT consortium</gtr:description><gtr:id>3133E186-228D-42EF-A7EC-292FF4681586</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>The ONE study - FP7 Consortium</gtr:description><gtr:id>5C2FEC88-C257-4292-BC9B-15799C7FE081</gtr:id><gtr:impact>Few manuscripts submitted.</gtr:impact><gtr:partnerContribution>Use of different cell type with the aim to induce tolerance in renal transplant patients.</gtr:partnerContribution><gtr:piContribution>Use of regulatory Tregs for the induction of tolerance in renal transplant patients.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hull and East Yorkshire Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GAMBIT consortium</gtr:description><gtr:id>35066482-234A-453A-8AD2-AB762FDA6363</gtr:id><gtr:impact>Congress communications:

1. September 2013, EACME Annual Conference 2013. Harrington, J, Cronin, A, Hilton R, GAMBIT Consortium, Sacks S, Lechler R, Hernandez-Fuentes M, Rebollo-Mesa I, Morgan, M. &amp;quot;A patient-centred approach to biomarkers of (transplant) tolerance&amp;quot;. Bochum, Germany
2. May 2013. American Transplant Congress 2013. M Jenkins, M Runglall, I Rebollo-Mesa, P Mobillo, Y Kamra, E Nova-Lamperti, S Norris, GAMBIT Consortium, G Lord, R Lechler and M Hernandez-Fuentes.Tolerance Related Gene Expression in Urine from Kidney Transplant Recipients. USA
3. May 2013. American Transplant Congress 2013. I Rebollo-Mesa, P Mobillo, E Nova-Lamperti, S Norris, Y Kamra, M Runglall, GAMBIT Consortium, Immune Tolerance Network, Indices of Tolerance Consortium, G Lord, R Lechler and MP Hernandez-Fuentes. Three-gene signature of tolerance for clinical application in kidney transplant recipients. USA
4. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Mobillo P, Norris S, Rebollo-Mesa I,Nova-Lamperti E, Kamra Y, Lord G, Vaughan R, Lechler R and Hernandez-Fuentes M. Title: Absence of Anti-Donor Specific Antibodies in Drug-Free Tolerant Kidney Transplant Recipients. Berlin 
5. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Rebollo-Mesa I, Norris S, Norris S, Nova-Lamperti E, Mobillo P, Runglall M, Kamra Y, Perucha E, Lord G, Lechler R and Hernandez-Fuentes M. A Validated RT-PCR Based Gene Signature for Tolerance in Kidney Transplant Recipients. Berlin
6. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Norris S, Nova-Lamperti E, Mobillo P, Kamra Y, Runglall M, Rebollo-Mesa I, Lord G, Lechler R and Hernandez-Fuentes Maria. From Bench to Clinic: Translating Biomarkers of Tolerance in Renal Allograft Recipients. Berlin
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Runglall M, Rebollo-Mesa I, Mobillo P, Norris S, Kon SP, Tucker B, Farmer CKT, Lord G, Storm T, Sacks SH, Hernandez-Fuentes M and Chowdhury P. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially Stratify Risk of Rejection Following Renal Transplantation. Berlin
8. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Nova-Lamperti E, Norris S, Mobillo P, Rebollo-Mesa I, Kamra Y, Lord G, Lechler R and Hernandez-Fuentes M. Higher IL10 Production by Transitional B Cells in Tolerant Kidney Transplant Recipients. Berlin
9. May 2012, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo-Mesa, Cook T, , Hernandez-Fuentes and Dorling A. Chronic Antibody-Mediated Rejection: B-Cell Dependent Alloreactive IFN?-Producing CD4+ T Cells Could Be Used as a Biomarker To Determine Responsiveness to Therapy. Am JTransplant Vol 12, Suppl 3, Abstract #1303.
10. May 2012, AMERICAN TRANSPLANT CONGRESS. Mikula M, Zhukov O, Hantash FM, , Hernandez-Fuentes MP, Sacks S, , and Naides SJ. A High Throughput Molecular Assay for Detection of Renal Graft Acute Cellular Rejection Using Peripheral Blood.. Am JTransplant Vol 12, Suppl 3, Abstract # LB48.
11. March 2012, 3rd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Chowdhury P, Rebollo-Mesa I, Runglall M, Mobillo P, Norris S, Kon SP, Tucker B, Farmer C, Lord G, Strom T, Sacks S and Hernandez-Fuentes M. Messenger RNA Levels in Peripheral Blood and Urine Can Potentially be used to Stratify Risk of Rejection Following Renal Transplantation. La Jolla, USA
12. February, 2012, BTS 15TH ANNUAL CONGRESS. P. Mobillo, S. Norris E. Nova-Lamperti, I. Rebollo-Mesa, M. Runglall, Y. Kamra, E Perucha, H Wilson, R. Lechler, G. Lord &amp;amp; M. Hernandez-Fuentes. GAMBIT Update: Translating to the Clinic Biomarkers of Tolerance in Renal Allograft Recipients. Glasgow 
13. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Nova-Lamperti E, Norris S, Lechler R, Lombardi G, Lord G and Hernandez-Fuentes M. Expression of B cell genes related with tolerance in kidney transplant recipients. Nantes 
14. June 2011, BASIC SCIENCE SYMPOSIUM 2011. Norris S, Nova-Lamperti E, Runglall M, Kamra Y, Mobillo P, Lechler R, Lord G, Hernandez-Fuentes M. Translating to the clinic biomarkers of tolerance in renal allograft recipients. Cape Cod, USA.
15. April 2011, AMERICAN TRANSPLANT CONGRESS. Cherukuri A, Carter C, Smalle N, Hernandez-Fuentes M, et al. Alemtuzumab Induction Leads to a Peripheral Regulatory B Cell Phenotype That Correlates with Graft Function. Am JTransplant Vol 11, Suppl 2, Abstract #204
16. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. CD4+ T Cells IFN?-Production Strongly Predicts Future Graft Dysfunction in Patients with Chronic Antibody-Mediated Rejection (CAMR) Diagnosed on Protocol Biopsy. Am JTransplant Vol 11, Suppl 2, Abstract #550 
17. April 2011, AMERICAN TRANSPLANT CONGRESS. Shiu KY, Rebollo Mesa I, Perucha E, , Hernandez-Fuentes M and Dorling A. Alloreactive IFN?-Producing CD4+ T Cells from Renal Transplant Recipients with Chronic Antibody-Mediated Rejection (CAMR) Are B-Cell Dependent In Vitro. Am JTransplant Vol 11, Suppl 2, Abstract #551
18. December 2010, BSI Annual Congress. Norris S, Nova-Lamperti E, Lechler R, Lord G and Hernandez-Fuentes M. Natural Killer Cell Subset Distribution in Renal Allograft Recipients. Liverpool, UK
19. December 2010, BSI Annual Congress. Nova-Lamperti, Norris S, Lechler R, Lord G and Hernandez-Fuentes MP. Expression of B Cell Genes Related with Tolerance in Kidney Transplant Recipients. Liverpool, UK
20. December 2010, BSI Annual Congress. Afzali B, Mitchell PJ, Scotta C, , Hernandez-Fuentes M, Lechler RI, and Lombardi G. Differential Suppression of Na&amp;iuml;ve and Memory Human CD4+ CD25- Cells By Naturally Occuring CD4+CD25+ Regulatory T Cells In Vitro. Liverpool, UK
21. May 2009, American Transplant Congress 2009. Hernandez-Fuentes M, Perucha P, Sagoo P, et al. Validated Biomarkers of Immune Tolerance in Renal Transplants. Am JTransplant Vol 9, Suppl 2, Abstract #1561

Conferences:

1. July 2013. Rebollo Mesa I et al. &amp;quot;Incorporating Patients' Preferences in the Development, Evaluation and Application of Biomarker Tests&amp;quot;. Birmingham.
2. May 2013, Uppsala University, Title: &amp;quot;Update on the GAMBIT study: towards a clinical trial of immunosuppression weaning&amp;quot;. Uppsala, Sweden
3. April 2013, 4th International Conference of Transplantomics and Biomarkers in Organ Transplantation. Title: Indicators of tolerance. Cambridge, UK
4. March 2013, BTS 16th ANNUAL CONGRESS. Title: Genetic biomarkers for translational research. Bournemouth, UK 
5. November 2012, Seminars programme of Universidad de Antioquia, Title: Biomarcadores de utilidad cl&amp;iacute;nica en transplante renal. Medellin, Colombia
6. September, 2012, Biomarker European Summit. Title: Personalising Post-transplant Care: Biomarkers of Clinical Utility for Kidney Transplant Recipients. Zurich, Switzerland.
7. July, 2012, 24th INTERNATIONAL CONGRESS OF THE TRANSPLANTATION SOCIETY. Title: Mechanisms of Tolerance. Berlin 
8. May, 2012, BIOMARKERS WORLD EUROPE. Title: Discovering biomarkers of clinical utility. London 
9. February, 2012, BTS 15TH ANNUAL CONGRESS. Title: The molecular signature of tolerance. Glasgow 
10. October, 2011, 56th SEFH CONGRESS 2011. Title: Biomarkers in relation to the efficacy and safety of immunosuppressant treatment of transplant patients. Coruna, Spain 
11. October, 2011, Innovative strategies to prevent transplant rejection. Title: Immunemonitoring in renal transplant patients. Sorrento, Italy 
12. September, 2011, 15th Congress of the European Society of Transplantation. Title: Biomarkers of kidney rejection in organ transplantation. Glasgow
13. June, 2011, BASIC SCIENCE SYMPOSIUM 2011. Invited to be one of the session moderators. Cape Cod, USA
14. June, 2011, 17th N.A.T. Meeting (Nantes Actualit&amp;eacute;s Transplantation). Title: Research of signature of tolerance in immunosuppressed patients: clinical protocols. Nantes
15. May, 2011, Biomarker World Europe conference. Title: Biomarkers of clinical utility in transplantation. London
16. March, 2011, 11th Congress of the Catalan Transplantation Society. Title: Regulatory lymphocyte subsets and graft clinical outcome. Barcelona
17. March, 2011, 2nd International Conference on Transplantomics and Biomarkers in Organ Transplantation. Congress organizer. Title: Biomarkers of Tol/CR in Kidney Transplantation. Barcelona
18. February, 2011, Joint Meeting Renal Association Soci&amp;eacute;t&amp;eacute; de N&amp;eacute;phrologie. Title: Regulatory B cells in tolerant transplant patients. Paris
19. February, 2011, Siemens European Symposium on Clinical and Translational Immunosuppression. Title: Immune B and T cell monitoring: biomarkers of tolerance. Barcelona
20. November 11, 2010: Clinical review for NEDERLANDSE TRANSPLANTATIE VERENIGING. Title: &amp;quot;How to Measure Tolerance&amp;quot;
21. September 24, 2010; II Symposium on Advances in Translational Immunology in Transplantation, Oviedo, Spain. Title &amp;quot;Indices de tolerancia Monitorizacion Inmunologica. 
22. August 18, 2010, XXIII International Congress of The Transplantation Society, member of the Basic Science committee and chair of session on Experimental and Human Tolerance.
23. July 6, 2010: Title: &amp;quot;Tolerogenic signatures; lessons from the transplant clinic&amp;quot;. Meeting: Biological Therapy: Scientific and Clinical Rationale. St Thomas' Hospital, London UK.
24. June 3, 2010: Title: &amp;quot;RISET: consensus on tolerance markers in kidney transplantation&amp;quot;. Meeting: 1st Meeting of the Spanish Society for Transplantation SET. Sevilla, Spain.
25. October 19, 2009: Title: Biomarkers of Tolerance in Kidney Transplantation: from discovery to translation&amp;quot;. Seminar Series: Section of Immunogenetics and Transplantation Immunology. Leiden University Medical Center 
26. September 17, 2009. &amp;quot;Biomarkers of Tolerance in Kidney Transplantation&amp;quot; British Society for Histocompatibility and Immunogenetics., Royal Armouries, Leeds

Peer Review publications:
NB: Main publications from the funded work have not been published yet. We expect to submit before the end of the year.

PMID: 22797727
PMID: 22390816
PMID: 22219224
PMID: 22151236.
PMID: 21749646
PMID: 21655296
PMID: 21909115
PMID: 21061447
PMID: 20659087

Review Articles in Journals
PMID:23838646
PMID: 23574313
PMID: 23283248
KIDNEY INT Sup 2011; 1: 40-46. 
PMID: 20717098
(2010) TRENDS IN TRANSPLANT 4:68-67.</gtr:impact><gtr:partnerContribution>- Recruitment of eligible patients into a clinical study
- Follow up and collection of samples from recruited patients
- Provision of clinical data required for the study
- Intellectual contribution to the study design.</gtr:partnerContribution><gtr:piContribution>I am the lead investigator and my team is the coordinator of the study. We have designed the study, obtained funding, coordinated samples, did all sample collection and all research laboratory analysis, and coordinated clinical data collection. We have matched the clinical data to the laboratory results, still doing the necessary analysis to maximise the outputs of this research.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute for Clinical and Experimental Medicine (IKEM)</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:description>BIO-DrIM. FP7 - Consortium</gtr:description><gtr:id>A0CFF4A1-96AE-46F8-8E6A-5E37214E8991</gtr:id><gtr:impact>None published yet</gtr:impact><gtr:partnerContribution>The central focus of the project is the implementation of biomarker-driven strategies for personalizing IS to improve the long-term outcome and to decrease the adverse effects and costs of chronic IS. This includes
5 innovative investigator-driven biomarker clinical trials designed by the consortium with &amp;gt;1800 (screening) / 1000 (trial) patients. The following issues will be addressed: -targeted complete/partial weaning of standard
IS in long-term stable liver and kidney Tx patients identified as &amp;quot;operationally tolerant&amp;quot; by recently developed biomarker panels-prevention of CNI-based standard IS in low-responder kidney Tx recipients by perioperative biomarker-based stratification-shifting high to low-responder kidney Tx patients suitable for early minimisation by the recently explored selective targeting of alloreactive effector/memory T cells -implementing new biomarker candidates supporting personalized IS within the clinical trials-analysing the health-economic impact of biomarker-guided personalized IS -studying the mechanisms behind successful weaning (regulation/effector balance) -disseminating the results and developing commercialisation by partnering with SME/industry. The project will take advantage and exploit recent research findings-Indices of Tolerance (IOT) and RISET but also of other international groups.</gtr:partnerContribution><gtr:piContribution>Bio-DrIM. Personalized minimization of immunosuppression after solid organ
transplantation by biomarker-driven stratification of patients to improve long-term outcome
and health-economic data of transplantation

King's College London will do 2 studies on WP1 and will drive all of the analysis work on WP4 of this consortium. Maria Hernandez-Fuentes is the lead investigator in KCL.

STUDY I, led by Prof Sanchez-Fueyo: A randomized multicentre controlled clinical study to assess the benefit/risk ratio of completely withdrawing IS in stable liver recipients identified as operationally tolerant on the basis of a liver tissue-based transcriptional test of tolerance. The study will test two hypotheses. First, that IS withdrawal is not inferior to IS maintenance in terms of rejection-related complications. Second, that drug withdrawal is superior to drug maintenance concerning the improvement of IS-related side effects.

STUDY III, led by Dr Hernandez-Fuentes: A UK multicentre randomised hybrid design biomarker clinical trial, where biomarker positive/negative patients will be separately randomized into two arms; the control arm will have standard
post-transplant follow up. The experimental arm will have a &amp;quot;Biomarker-led&amp;quot; follow up, namely, the strategy for their management will use the information obtained with the tolerance signature. The peripheral blood biomarker
tolerance profile described by IOT/RISET (set-1 WP4) will be used in the biomarker led group to offer partial IS
weaning to positive patients.

WP 4.2 led by Dr Rebollo-Mesa. To organize data management and biostatistics. Establishment of a Central data base and data management system; biostatistical analyses of clinical and laboratory results, including ontology between the studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Media Interest (SRUK)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1346E736-6306-48FA-925B-E65FF0AAB665</gtr:id><gtr:impact>Mar&amp;iacute;a Hern&amp;aacute;ndez Fuentes, vice-president of SRUK/CERU talks about the brain drain happening in Spain and the difficulties that emigrated scientists face when trying to return.

no known</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.zoomnews.es/105358/actualidad/mundo/cientificos-espanoles-extranjero-ven-cada-dia-mas-dificil-retorno</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr Mar?a Hern?ndez-Fuentes appeared in channel &quot;La Sexta&quot;, program: Constantes y Vitales, Spain</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BB4BDAF8-F63D-4A9D-BC57-0ABD52D109CA</gtr:id><gtr:impact>Interview to talk about the differences in the situation of science and scientists between Spain and UK</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.lasexta.com/constantes-vitales/noticias/investigadores-insisten-que-ciencia-puede-ser-motor-recuperacion-espanola_2015010600078.html</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RTVE interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4B617B04-0957-4202-A54C-2B587052A101</gtr:id><gtr:impact>Dr Mar&amp;iacute;a Hern&amp;aacute;ndez-Fuentes appeared in RTVE to talk about the differences we observed in science culture between the UK and Spanish societies

no known</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.rtve.es/alacarta/videos/europa/europa-2013-27-09-13/2034251</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Vice President of Society of Spanish Researchers in the United Kingdom</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>618B1399-6E49-4BCE-BBAD-38AE1D2C9144</gtr:id><gtr:impact>Acting as a Vice President of the Society to:

a) Create a social network of researchers and students working in the UK
b) Increase social awareness of R&amp;amp;D in the Spanish and British societies
c) Represent its membership before Spanish and British Institutions and media
d) Establish collaborations between Spanish and British Institutions


On 2 occasions I have met with high officials in the Departments of Education and Industry from Spain (where science is embedded) and discussed possible evaluation systems for scientists. Possibly influencing policy in the evaluation framework to be set up in the future in Spain.
SRUK keeps a diverse programme of public engagement activities in the UK that are contributing to the general understanding of science.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.sruk.org.uk</gtr:url><gtr:year>2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Transplantation Morning 19/05/15</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>FE6322C1-F4E5-4CC5-92D2-622DC1AB3EB9</gtr:id><gtr:impact>A number of patients stopped at the stand where we were explaining current research studies they could participate on, whether observational or clinical trials</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centenary Event - Panel Debate - The Future of Transplantation 20 June 2013</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>4956B913-A72A-4659-89E1-048ABC589326</gtr:id><gtr:impact>Prof Lechler was the Panel member for panel discussion in MRC centre transplantation which covered the following topics:
1. Addressing and overcoming organ shortage in the UK - specifically, how can research help?
2. The use of stem cells for organ repair and replacement
3. The use of genetics research and individual genetic profiling ('barcodes') to predict transplant outcome
4. Public health, personal risk; the role of patient participation in experimental (transplant) medicine


Provided the opportunity to engage public to deepen their understanding of transplantation science.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr Hernandez-Fuentes participates in an online radio programme, Naukas www.naukas.com,</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EC0BA4D8-7A5D-486C-9857-A626CE0CA5D8</gtr:id><gtr:impact>Discussion about brain drain and brain gain and how to maximise the benefit of &amp;quot;scientist on the move&amp;quot;</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://naukas.com/2015/04/07/15a-tertulia-media2ciencia-ciencia-lejos-de-espana/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The Telegraph</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>842AB30B-CDB4-4D73-B94D-5413C7147FE1</gtr:id><gtr:impact>Discussions of immune tolerance with the The Telegraph, which was published as an article on 26th May 2010


Gained exposure of the biomarkers of tolerance to the The Telegraph which a subsequent article published</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Channel 4 news</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>35E1F5E9-317E-4F58-93DA-0BFBA027B8D1</gtr:id><gtr:impact>Discussions of immune tolerance with Channel 4 news, which was published as an article and featured on the news in May 2010

Gained exposure of the biomarkers of tolerance to Channel 4 news which a subsequent article published</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nature</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E653F729-2165-411A-8D92-888095AA310E</gtr:id><gtr:impact>Nature mentioned SRUK as one of the networking organisations of scientists in the UK

This has contributed to dissemination of science to the general public.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.sruk.org.uk/documents/on-the-media/20121122-Nature%20Jobs.pdf</gtr:url><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Hispan TV La Gran Historia - Donaci?n de ?rganos en Uruguay</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>98C57672-1BB3-476D-9910-C7D90041E61B</gtr:id><gtr:impact>I discussed the benefits of transplantation for society and the importance in Research in this field</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BRC PPI event for GAMBIT and DECISIONS</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>236A0B95-9D8E-47EE-B053-F194092C4924</gtr:id><gtr:impact>?

n/a</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Team Participation in Clinical Trials Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>BBA754C0-6B0E-4B57-B07B-C688C1762C5B</gtr:id><gtr:impact>Open day to explain active clinical trials in the Division of Transplantation at Guy's Hospital</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Chair, Women and Science Roundtable</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2F0E9BCF-837D-4769-B9CE-4FE5CFB82849</gtr:id><gtr:impact>Organised by The Office for Cultural and Scientific Affairs of the Embassy of Spain (OCSA) and SRUK/CERU

Part1: http://vimeo.com/98850732 . Part 2: http://vimeo.com/99146100</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Active participation in &quot;Science Week&quot; Instituto Caniada Blanch, Portobello, London</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B97AD478-B02E-4D46-898F-82692454D259</gtr:id><gtr:impact>Around 40 students attended two sessions in the school where we explained how to conduct a clinical trial and what questions can be answered with this. Also what ethical implications the set up and pariticipation in a clinical trial arises.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Kidney Patient Association website</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>FC988C7D-F020-4A2A-9D6E-3851821F6F93</gtr:id><gtr:impact>An online article of the GAMBIT study on KPA website.

Disseminated the brief summary of the GAMBIT study to patients and public.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr Maria Hernandez-Fuentes, appeared in a radio programme based in Toledo, Spain,&quot;LUCIERNAGAS - CIENCIA AL DIA&quot;</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B3B6B5CF-C21F-4919-888D-C19B7AE0FEA6</gtr:id><gtr:impact>I explained aims of the society Spanish Researchers in the UK and about transplantation science</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://ciencia-luciernagas.blogspot.com.es/2015/04/srukceru-sociedadcientificos-espanoles.html</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr Hernandez-Fuentes with Dr Rebollo-Mesa actively participate in &quot;Science Week&quot; Instituto Caniada Blanch, Portobello, London</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>B4FFA6DF-AF8D-422B-8962-F08D5376C8B8</gtr:id><gtr:impact>We explained how a clinical trial works by actively participating in a trial testing different breakfasts.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>King's College London</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5E09B295-2BAD-433F-BF19-A40F7773A368</gtr:id><gtr:impact>Discussions of immune tolerance with King's College London, which was published as an article and featured on the news on 25th May 2010

Gained exposure of the biomarkers of tolerance to King's College London which a subsequent article published</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference on Research &amp; Innovation for the Development &amp; Growth</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8E4AAFB6-D7A3-437A-AF78-4B7D64091E53</gtr:id><gtr:impact>Attended the Conference on Research &amp;amp; Innovation for the Development &amp;amp; Growth, organized by &amp;quot;Europa en Suma&amp;quot;, Madrid 
Programme in Spanish: http://europaensuma.org/la-europa-excelente-innovacion-e-investigacion 
Short video of my contribution (in Spanish) : http://www.europaensuma.org/videos-jornada/vervideo/17/jornada-la-europa-excelente/la-europa-excelente-ponente-maria-hernandez-fuentes 


I was asked to do an interview on a TV programme for to discuss the future of science in Spain. This has contributed to dissemination of science to the general public.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://europaensuma.org/la-europa-excelente-innovacion-e-investigacion</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>STEM Ambassador visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>B61835E3-DE9B-41F6-BABF-4F331B0F5145</gtr:id><gtr:impact>STEM Ambassador visit. &amp;quot;Meet the professional session&amp;quot; for sixth form students before they choose their chosen subject in the university. I gave a talk about my own career choice and steps that I took to become a scientist. There was a session of questions and answers on different future possibilities.

This has contributed to dissemination of science to the general public/students. Expected impacts on student subject choice and enhanced their understanding of career path as a scientist.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.inspiringfutures.org.uk</gtr:url><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Transplantation-tolerance website</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7AC5A985-E2D1-41C3-8B17-D95093C4B9F7</gtr:id><gtr:impact>This website updates participants, physicians and the general public of the progress in the project.


A small number of patients have seen this and other websites about transplantation-tolerance and have contacted the PI subsequently.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Spanish Embassy in London celebrates a Seminar on Science Diplomacy</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>815821F8-EB72-427A-8D24-703D65EC115B</gtr:id><gtr:impact>This seminar raised great expectation among the diplomatic community in London, and between academic and scientific institutions, which was attended by a large representation of these sectors.

The seminar had two main objectives: to have a good knowledge of the best practices of scientific diplomacy carried out by leading countries in research and innovation but also in developing nations. The other aim was to identify the most favourable opportunities for scientific mobility</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:url>http://www.spainculturescience.co.uk/es/noticias/la-embajada-de-espa%C3%B1a-en-londres-organiza-un-seminario-sobre-diplomacia-cient%C3%ADfica</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Europa 2013</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>63A09975-6E37-4BBD-89B2-5A8FE6483696</gtr:id><gtr:impact>Appeared in RTVE to talk about the differences we observed in science culture between the UK and Spanish societies: minute 25:26

Public dissemination of science culture.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.rtve.es/alacarta/videos/europa/europa-2013-27-09-13/2034251/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science week Instituto Canada Blanch</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B3C6C162-142E-4E2A-B674-388CAEFCE092</gtr:id><gtr:impact>talk sparked questions and discussion

ignited interest in students</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture in Science week at Instituto Canada Blanch</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F8CAFA09-8317-4B1E-86E4-CC4EEB8943CC</gtr:id><gtr:impact>Lecture in Science week at Instituto Canada Blanch (Spanish Primary &amp;amp; Secondary School ). 

http://monix.a.tripod.com/spanish_school_london/welcome.html 

29 May 2012 Title of lecture: What is a clinical Trial?
10 May 2013 Title: Transplantation: History and ethical issues

This has contributed to dissemination of science to the general public.
School has asked for a visit next year, which we will do.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.sruk.org.uk/documents/press-releases/130430-SRUKScienceWeek-Eng.pdf</gtr:url><gtr:year>2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>New Scientist</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>12C1F78C-5D5E-4FAB-BE17-BC948F6D5DF7</gtr:id><gtr:impact>Discussions of immune tolerance with the New Scientist, regarding an idea of an article for organ transplantation


Gained exposure of the biomarkers of tolerance to the New Scientist</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Zoomnews</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8A684125-9AA3-42B8-8D03-9352FB296511</gtr:id><gtr:impact>talked about the brain drain happening in Spain and the difficulties that emigrated scientists face when trying to return.

This has contributed to dissemination of science to the general public.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.zoomnews.es/105358/actualidad/mundo/cientificos-espanoles-extranjero-ven-cada-dia-mas-dificil-retorno</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>GAMBIT - DECISION Patient information event</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>477066F2-9D6B-4F42-AEDE-0021E9ABDFEF</gtr:id><gtr:impact>On the We reported to participants the main results for the main results of the study funded by the MRC award - with the help of the added funding - the study is called &amp;quot;GAMBIT&amp;quot; but also the social science part of the study DECISIONS. Participants were very grateful that we have done the effort of communicating the results and tell them about the plans for the projects.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://www.kcl.ac.uk/lsm/research/divisions/timb/research/tolerance/gambit/index.aspx</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Reuters</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7ECE49D8-9178-4515-9CF8-8A3DEB718036</gtr:id><gtr:impact>Discussions of immune tolerance with the Reuters news agency, which was published as an article on 25th May 2010

Gained exposure of the biomarkers of tolerance to the Reuters news agency which a subsequent article published</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>10000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>RISET - (Reprogramming the Immune system for the establishment of tolerance).</gtr:description><gtr:end>2008-12-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:fundingRef>QLK3-CT-2002-02127</gtr:fundingRef><gtr:id>E0E9EE72-1DF4-4472-A780-58DED2BEB5BB</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2003-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500</gtr:amountPounds><gtr:country>Canada</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>TTS - Mentor Mentee Award</gtr:description><gtr:end>2012-07-02</gtr:end><gtr:fundingOrg>Transplantation Society</gtr:fundingOrg><gtr:id>CAF0F279-A5D0-421D-A985-FF529910EA1D</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>127000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>WTCCC3 Core Activities: Defining the genetic basis for interactions between donor and recipient DNA that determine early and late renal transplant dysfunction</gtr:description><gtr:end>2012-05-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>088849/Z/09/Z</gtr:fundingRef><gtr:id>9EE2385B-EF3A-4238-B918-DB9FD827C595</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BRC Interdisciplinary programme</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Guy's and St Thomas' NHS Foundation Trust</gtr:fundingOrg><gtr:id>1D1D1C53-5AE9-4C61-B0E1-C0357A3169D5</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>135518</gtr:amountPounds><gtr:country>Chile, Republic of</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>CONICYT - PhD</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>National Commission for Scientific and Technological Research (CONICYT)</gtr:fundingOrg><gtr:fundingRef>72090270, Year 2009</gtr:fundingRef><gtr:id>BAD3A656-E17E-4C11-86A8-15225981FFA2</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>127000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Guy's &amp;amp; St Thomas' Charity</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Guy?s &amp; St Thomas? Charity</gtr:fundingOrg><gtr:fundingRef>R090782</gtr:fundingRef><gtr:id>1DFEC114-F822-4502-B248-32EC5ED131BD</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>17000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Guy?s and St Thomas? Kidney Patients' Association (GSTT KPA)</gtr:department><gtr:description>KPA Research support</gtr:description><gtr:end>2012-05-02</gtr:end><gtr:fundingOrg>Guy's and St Thomas' NHS Foundation Trust</gtr:fundingOrg><gtr:id>8DE52D1F-BBE1-4245-A7A9-7C400F017296</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>260000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Guy's and St Thomas' Charity</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>Guy?s &amp; St Thomas? Charity</gtr:fundingOrg><gtr:fundingRef>R080530</gtr:fundingRef><gtr:id>2EEF537A-83DF-44D8-A70A-888F67623C6D</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>970000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>European Commission FP7 Health (The ONE study)</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Community Research and Development Information Service (CORDIS)</gtr:fundingOrg><gtr:id>8FCD6AF3-BA93-4863-B628-4E4662648C4C</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>850000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>European Commission FP7 Health (Bio-DRIM)</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>European Commission (EC)</gtr:fundingOrg><gtr:fundingRef>305147-2</gtr:fundingRef><gtr:id>370FC35E-5B85-427E-83D4-1518DCF942A7</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A method of determining an individual's transplantation tolerance by determining the level of a number of biomarkers.
The patent application PCT/GB2011/050874, priority date 4 May 2010, entitled &amp;quot;Method of Determining Tolerance&amp;quot;, will enter National Phase prosecution on 4 November 2012.
Assignees: King's College London, Charit&amp;eacute; - Universit&amp;auml;tsmedizin Berlin, Miltenyi Biotec GmbH
Inventors: Maria Hernandez Fuentes, Irene Rebollo Mesa, Birgit Sawitski, Hans-Dieter Volk, Uwe Janssen, Stefan Tomiuk</gtr:description><gtr:id>E87A81C8-9827-409E-B5F0-A1F71ADC977E</gtr:id><gtr:impact>A method of determining an individual's transplantation tolerance by determining the level of a number of biomarkers.</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:patentId>WO2011138609</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Method of Determining Tolerance</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Meeting with ANECA &amp;amp; General Director for University Policy about research quality evaluation in Spain</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>F25A3AB8-2C0D-487A-8A7B-212C446ABB60</gtr:id><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MSc in Translational Medicine</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>B77FBFD1-1DC8-40C4-99C3-BBECE83B5875</gtr:id><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Diagnostic Test to identify tolerance in kidney transplant recipients.
We are developing the application strategy for patients.
Needs a biomarker-led clinical trial that has not been funded yet.</gtr:description><gtr:id>58967683-A5BC-4610-BB9C-12FC5BC54963</gtr:id><gtr:impact>If the clinical trial shows clinical benefit for the patients who are in the biomarker-led group, we will have a tool to personalise the post-transplant management of a set of patients (5 - 15%) that will mean less immunosuppression, with the lower rate of secondary events this has and better quality of life.</gtr:impact><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>On hold</gtr:status><gtr:title>A method for evaluating transplantation tolerance</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Integration of anonimysed clinical data and &amp;quot;omics&amp;quot; for research and clinical purposes</gtr:description><gtr:id>0DD6187E-5A3B-4B73-82FA-D32D757D8DE0</gtr:id><gtr:impact>Not yet. It will facilitate research and clinical practice in a large scale</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>NIHR-HIC</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://www.nihr.ac.uk/about/hic.htm</gtr:url><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>cells
mRNA from blood
serum
urine mRNA
fresh urine</gtr:description><gtr:id>3F2B4ABA-1A1B-48A3-AB59-9BFE81939EF7</gtr:id><gtr:impact>Future biomarkers of tolerance to be developed.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>GAMBIT cell and mRNA collection</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D5B8E12F-9B96-4897-BB26-49A811BE7BC4"><gtr:id>D5B8E12F-9B96-4897-BB26-49A811BE7BC4</gtr:id><gtr:title>Biomarkers of Tolerance: Hope or hype?</gtr:title><gtr:parentPublicationTitle>Trends in Transplant</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/23a54e995ccd442861ef2f26669f0f60"><gtr:id>23a54e995ccd442861ef2f26669f0f60</gtr:id><gtr:otherNames>Hilton R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8BE45688-7A61-44B7-A378-8230323950A4"><gtr:id>8BE45688-7A61-44B7-A378-8230323950A4</gtr:id><gtr:title>Biomarkers of tolerance: searching for the hidden phenotype.</gtr:title><gtr:parentPublicationTitle>Kidney international supplements</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6115fc4c487dbba14324d62d7dbb77be"><gtr:id>6115fc4c487dbba14324d62d7dbb77be</gtr:id><gtr:otherNames>Perucha E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2157-1716</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/757F4109-9378-4281-88E1-DC3E46D4F5D0"><gtr:id>757F4109-9378-4281-88E1-DC3E46D4F5D0</gtr:id><gtr:title>Biomarkers of tolerance: searching for the hidden phenotype.</gtr:title><gtr:parentPublicationTitle>Kidney international supplements</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6115fc4c487dbba14324d62d7dbb77be"><gtr:id>6115fc4c487dbba14324d62d7dbb77be</gtr:id><gtr:otherNames>Perucha E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2157-1716</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6FAD1B51-0D17-4391-8EA5-4B5EA2ABFE86"><gtr:id>6FAD1B51-0D17-4391-8EA5-4B5EA2ABFE86</gtr:id><gtr:title>Biomarkers of tolerance.</gtr:title><gtr:parentPublicationTitle>Current opinion in organ transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/29dcf1b4d5dd496e0c0d7f8aefbe6b29"><gtr:id>29dcf1b4d5dd496e0c0d7f8aefbe6b29</gtr:id><gtr:otherNames>G?kmen R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1087-2418</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DDEBAFEE-29A6-4D90-BCEB-DC9DAD8FA85D"><gtr:id>DDEBAFEE-29A6-4D90-BCEB-DC9DAD8FA85D</gtr:id><gtr:title>B-lymphocytes support and regulate indirect T-cell alloreactivity in individual patients with chronic antibody-mediated rejection.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/25ee74e60fac27a1dbf2c03b22f0cff8"><gtr:id>25ee74e60fac27a1dbf2c03b22f0cff8</gtr:id><gtr:otherNames>Shiu KY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/04EC1FD9-7131-4B5D-B999-FD094E9B0FBF"><gtr:id>04EC1FD9-7131-4B5D-B999-FD094E9B0FBF</gtr:id><gtr:title>A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/106c16d6f9893f7a7d87dd13518ba4f7"><gtr:id>106c16d6f9893f7a7d87dd13518ba4f7</gtr:id><gtr:otherNames>Canavan JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7F5AA886-A4A3-44D1-85A0-95A6D040B1E9"><gtr:id>7F5AA886-A4A3-44D1-85A0-95A6D040B1E9</gtr:id><gtr:title>Analysis of the peripheral T-cell repertoire in kidney transplant patients.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e70e4dbfcfff0622bdae9402f8d769c4"><gtr:id>e70e4dbfcfff0622bdae9402f8d769c4</gtr:id><gtr:otherNames>Miqueu P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C7B29436-7795-4048-8DE0-3167EA1B3A35"><gtr:id>C7B29436-7795-4048-8DE0-3167EA1B3A35</gtr:id><gtr:title>Promoting transplantation tolerance; adoptive regulatory T cell therapy.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f8f79b3b082d0af0f2cd8470d59b7efb"><gtr:id>f8f79b3b082d0af0f2cd8470d59b7efb</gtr:id><gtr:otherNames>Safinia N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2B938FDF-21F9-49C9-8B8C-BA9AA32B10BF"><gtr:id>2B938FDF-21F9-49C9-8B8C-BA9AA32B10BF</gtr:id><gtr:title>Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/570799dafea994d041cee77644b69946"><gtr:id>570799dafea994d041cee77644b69946</gtr:id><gtr:otherNames>Sagoo P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/92475994-2EE7-4200-99E7-E5F7CEE56E97"><gtr:id>92475994-2EE7-4200-99E7-E5F7CEE56E97</gtr:id><gtr:title>Identification of a B cell signature associated with renal transplant tolerance in humans.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a85aaa5d8d6db3211a549cf016563839"><gtr:id>a85aaa5d8d6db3211a549cf016563839</gtr:id><gtr:otherNames>Newell KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/68A3C025-49F5-4225-87F4-339BA84DB910"><gtr:id>68A3C025-49F5-4225-87F4-339BA84DB910</gtr:id><gtr:title>Translational mini-review series on Th17 cells: induction of interleukin-17 production by regulatory T cells.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a24f02668e536a6d0df0cd985e178d88"><gtr:id>a24f02668e536a6d0df0cd985e178d88</gtr:id><gtr:otherNames>Afzali B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EF520785-D021-46A7-94AE-B75CF3CAA358"><gtr:id>EF520785-D021-46A7-94AE-B75CF3CAA358</gtr:id><gtr:title>Relevance of regulatory T cell promotion of donor-specific tolerance in solid organ transplantation.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/570799dafea994d041cee77644b69946"><gtr:id>570799dafea994d041cee77644b69946</gtr:id><gtr:otherNames>Sagoo P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B987FD7D-970B-4DD0-AB69-E5A81D617CB1"><gtr:id>B987FD7D-970B-4DD0-AB69-E5A81D617CB1</gtr:id><gtr:title>The T helper 17-regulatory T cell axis in transplant rejection and tolerance.</gtr:title><gtr:parentPublicationTitle>Current opinion in organ transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/42efcedd0dc9c06e83d06fa56f48575f"><gtr:id>42efcedd0dc9c06e83d06fa56f48575f</gtr:id><gtr:otherNames>Mitchell P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1087-2418</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/193A5DFC-4552-4066-AA7D-027C2ED609ED"><gtr:id>193A5DFC-4552-4066-AA7D-027C2ED609ED</gtr:id><gtr:title>Biomarkers of tolerance.</gtr:title><gtr:parentPublicationTitle>Current opinion in organ transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/29dcf1b4d5dd496e0c0d7f8aefbe6b29"><gtr:id>29dcf1b4d5dd496e0c0d7f8aefbe6b29</gtr:id><gtr:otherNames>G?kmen R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1087-2418</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/016667B5-51DA-478F-A14B-9DAF10A8BB21"><gtr:id>016667B5-51DA-478F-A14B-9DAF10A8BB21</gtr:id><gtr:title>Cutting Edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/27e32a19b7843d2a44f2e7cde6911b83"><gtr:id>27e32a19b7843d2a44f2e7cde6911b83</gtr:id><gtr:otherNames>Hutchinson JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ED0893FE-A03D-474B-81E1-B81B1370593F"><gtr:id>ED0893FE-A03D-474B-81E1-B81B1370593F</gtr:id><gtr:title>Donor-specific indirect pathway analysis reveals a B-cell-independent signature which reflects outcomes in kidney transplant recipients.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e6f7ac80019ab6e023268463ea9c67dd"><gtr:id>e6f7ac80019ab6e023268463ea9c67dd</gtr:id><gtr:otherNames>Haynes LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4CA23267-0484-4A8E-BEAD-EA4697130224"><gtr:id>4CA23267-0484-4A8E-BEAD-EA4697130224</gtr:id><gtr:title>Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f6428f92de0bfb11f802069857dd60ce"><gtr:id>f6428f92de0bfb11f802069857dd60ce</gtr:id><gtr:otherNames>Bacchetta R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BB313BEE-DFFA-4CC2-B173-16F1FA03DABC"><gtr:id>BB313BEE-DFFA-4CC2-B173-16F1FA03DABC</gtr:id><gtr:title>Relative resistance of human CD4(+) memory T cells to suppression by CD4(+) CD25(+) regulatory T cells.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a24f02668e536a6d0df0cd985e178d88"><gtr:id>a24f02668e536a6d0df0cd985e178d88</gtr:id><gtr:otherNames>Afzali B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/16B65B63-4202-406B-903A-244958D559DA"><gtr:id>16B65B63-4202-406B-903A-244958D559DA</gtr:id><gtr:title>Non-invasive biomarkers to guide management following renal transplantation: the need for a multiplatform approach.</gtr:title><gtr:parentPublicationTitle>Current opinion in organ transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ce71fe9aea464999cf689aa64bf424e9"><gtr:id>ce71fe9aea464999cf689aa64bf424e9</gtr:id><gtr:otherNames>Chowdhury P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1087-2418</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BA9CEDA2-4248-4251-994F-2FF5B0A4E9EC"><gtr:id>BA9CEDA2-4248-4251-994F-2FF5B0A4E9EC</gtr:id><gtr:title>Biomarkers of Tolerance in Kidney Transplantation: Are We Predicting Tolerance or Response to Immunosuppressive Treatment?</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/43376703a6f3872ef7f7fdad69ee6e06"><gtr:id>43376703a6f3872ef7f7fdad69ee6e06</gtr:id><gtr:otherNames>Rebollo-Mesa I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9F176309-D114-4E54-B8C5-9E0B3F9EABFF"><gtr:id>9F176309-D114-4E54-B8C5-9E0B3F9EABFF</gtr:id><gtr:title>Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f6428f92de0bfb11f802069857dd60ce"><gtr:id>f6428f92de0bfb11f802069857dd60ce</gtr:id><gtr:otherNames>Bacchetta R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/66296214-19BB-497F-A31B-8AD26E3B9F08"><gtr:id>66296214-19BB-497F-A31B-8AD26E3B9F08</gtr:id><gtr:title>Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4(+)CD25(+)FOXP3(+) T regulatory cell subpopulations.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a501a6a9751751d9907ecb97f8214a5f"><gtr:id>a501a6a9751751d9907ecb97f8214a5f</gtr:id><gtr:otherNames>Scott? C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1078DC4F-BEB5-4A84-A8DD-C44B8B0EDDF2"><gtr:id>1078DC4F-BEB5-4A84-A8DD-C44B8B0EDDF2</gtr:id><gtr:title>Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/106c16d6f9893f7a7d87dd13518ba4f7"><gtr:id>106c16d6f9893f7a7d87dd13518ba4f7</gtr:id><gtr:otherNames>Canavan JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/77749C26-8918-4979-A222-7CFCD6A10E5D"><gtr:id>77749C26-8918-4979-A222-7CFCD6A10E5D</gtr:id><gtr:title>Immunologic human renal allograft injury associates with an altered IL-10/TNF-a expression ratio in regulatory B cells.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c5f44bb44b03638a9aaf1c176153f1c0"><gtr:id>c5f44bb44b03638a9aaf1c176153f1c0</gtr:id><gtr:otherNames>Cherukuri A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/43793B36-92EC-4792-83EE-445649C6779A"><gtr:id>43793B36-92EC-4792-83EE-445649C6779A</gtr:id><gtr:title>Differential role of na&amp;iuml;ve and memory CD4 T-cell subsets in primary alloresponses.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3360b2a482e59542791f812853ec0450"><gtr:id>3360b2a482e59542791f812853ec0450</gtr:id><gtr:otherNames>Golshayan D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F0796596-57EE-454F-81D0-37F8CB775774"><gtr:id>F0796596-57EE-454F-81D0-37F8CB775774</gtr:id><gtr:title>Donor-specific indirect pathway analysis reveals a B-cell-independent signature which reflects outcomes in kidney transplant recipients.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e6f7ac80019ab6e023268463ea9c67dd"><gtr:id>e6f7ac80019ab6e023268463ea9c67dd</gtr:id><gtr:otherNames>Haynes LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/28072A47-7F71-416A-91F1-A57B6E82FD33"><gtr:id>28072A47-7F71-416A-91F1-A57B6E82FD33</gtr:id><gtr:title>An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c5f44bb44b03638a9aaf1c176153f1c0"><gtr:id>c5f44bb44b03638a9aaf1c176153f1c0</gtr:id><gtr:otherNames>Cherukuri A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/440B6FF9-882F-4908-ADF8-EE8D78646953"><gtr:id>440B6FF9-882F-4908-ADF8-EE8D78646953</gtr:id><gtr:title>Dendritic cells as a tool to induce transplantation tolerance: obstacles and opportunities.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ca7735af73bbaf5c97b6788a960d8e61"><gtr:id>ca7735af73bbaf5c97b6788a960d8e61</gtr:id><gtr:otherNames>van Kooten C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BBCB9934-6306-423D-B231-7314BFFF4967"><gtr:id>BBCB9934-6306-423D-B231-7314BFFF4967</gtr:id><gtr:title>A 'biomarker signature' for tolerance in transplantation.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/27d136cb0b10a6c9ffc7a02a0d6f2ffb"><gtr:id>27d136cb0b10a6c9ffc7a02a0d6f2ffb</gtr:id><gtr:otherNames>Hernandez-Fuentes MP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1759-5061</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A46A17B1-AEA2-4B15-B465-BBAEB59923B5"><gtr:id>A46A17B1-AEA2-4B15-B465-BBAEB59923B5</gtr:id><gtr:title>Comparison of regulatory T cells in hemodialysis patients and healthy controls: implications for cell therapy in transplantation.</gtr:title><gtr:parentPublicationTitle>Clinical journal of the American Society of Nephrology : CJASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a24f02668e536a6d0df0cd985e178d88"><gtr:id>a24f02668e536a6d0df0cd985e178d88</gtr:id><gtr:otherNames>Afzali B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1555-9041</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/16C4F6DF-ACCC-4750-9E4F-37AD210BEB5E"><gtr:id>16C4F6DF-ACCC-4750-9E4F-37AD210BEB5E</gtr:id><gtr:title>An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c5f44bb44b03638a9aaf1c176153f1c0"><gtr:id>c5f44bb44b03638a9aaf1c176153f1c0</gtr:id><gtr:otherNames>Cherukuri A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2DE3E6A7-2A25-4367-B4B2-90D21E6080B0"><gtr:id>2DE3E6A7-2A25-4367-B4B2-90D21E6080B0</gtr:id><gtr:title>Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/570799dafea994d041cee77644b69946"><gtr:id>570799dafea994d041cee77644b69946</gtr:id><gtr:otherNames>Sagoo P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CA4D27D0-259E-415D-A532-D411CA2B9084"><gtr:id>CA4D27D0-259E-415D-A532-D411CA2B9084</gtr:id><gtr:title>Circulating vascular progenitor cells and central arterial stiffness in polycystic ovary syndrome.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/808513999327fdecf2202b797b820f14"><gtr:id>808513999327fdecf2202b797b820f14</gtr:id><gtr:otherNames>Dessapt-Baradez C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/396707F8-C592-4A8B-B36B-CDBCE136B3B8"><gtr:id>396707F8-C592-4A8B-B36B-CDBCE136B3B8</gtr:id><gtr:title>Cross-validation of IFN-? Elispot assay for measuring alloreactive memory/effector T cell responses in renal transplant recipients.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/625f78e63e646ba55438bf4227e9d7f8"><gtr:id>625f78e63e646ba55438bf4227e9d7f8</gtr:id><gtr:otherNames>Bestard O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D415937F-6E67-46E0-98E0-E823B5D1F2FB"><gtr:id>D415937F-6E67-46E0-98E0-E823B5D1F2FB</gtr:id><gtr:title>Non-invasive biomarkers to guide management following renal transplantation: the need for a multiplatform approach.</gtr:title><gtr:parentPublicationTitle>Current opinion in organ transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ce71fe9aea464999cf689aa64bf424e9"><gtr:id>ce71fe9aea464999cf689aa64bf424e9</gtr:id><gtr:otherNames>Chowdhury P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1087-2418</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8C381841-27D0-4606-B114-18B2ED1E0488"><gtr:id>8C381841-27D0-4606-B114-18B2ED1E0488</gtr:id><gtr:title>Graft dysfunction in chronic antibody-mediated rejection correlates with B-cell-dependent indirect antidonor alloresponses and autocrine regulation of interferon-? production by Th1 cells.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/25ee74e60fac27a1dbf2c03b22f0cff8"><gtr:id>25ee74e60fac27a1dbf2c03b22f0cff8</gtr:id><gtr:otherNames>Shiu KY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C6851787-A95E-4003-8D08-0137EF809933"><gtr:id>C6851787-A95E-4003-8D08-0137EF809933</gtr:id><gtr:title>Identification of a B cell signature associated with renal transplant tolerance in humans.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a85aaa5d8d6db3211a549cf016563839"><gtr:id>a85aaa5d8d6db3211a549cf016563839</gtr:id><gtr:otherNames>Newell KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3733DB79-1B29-41DF-86AF-371D5ABFA5E5"><gtr:id>3733DB79-1B29-41DF-86AF-371D5ABFA5E5</gtr:id><gtr:title>Relative resistance of human CD4(+) memory T cells to suppression by CD4(+) CD25(+) regulatory T cells.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a24f02668e536a6d0df0cd985e178d88"><gtr:id>a24f02668e536a6d0df0cd985e178d88</gtr:id><gtr:otherNames>Afzali B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EDBC7D2F-652D-422F-B8EB-93F4FF1BE8A5"><gtr:id>EDBC7D2F-652D-422F-B8EB-93F4FF1BE8A5</gtr:id><gtr:title>Promoting transplantation tolerance; adoptive regulatory T cell therapy.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f8f79b3b082d0af0f2cd8470d59b7efb"><gtr:id>f8f79b3b082d0af0f2cd8470d59b7efb</gtr:id><gtr:otherNames>Safinia N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4CD739B7-D1EA-466A-9C81-5BEE5A0F9642"><gtr:id>4CD739B7-D1EA-466A-9C81-5BEE5A0F9642</gtr:id><gtr:title>Immunologic human renal allograft injury associates with an altered IL-10/TNF-a expression ratio in regulatory B cells.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c5f44bb44b03638a9aaf1c176153f1c0"><gtr:id>c5f44bb44b03638a9aaf1c176153f1c0</gtr:id><gtr:otherNames>Cherukuri A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/52A11817-4EC8-4AF5-966F-53881EC60648"><gtr:id>52A11817-4EC8-4AF5-966F-53881EC60648</gtr:id><gtr:title>Genome-wide regulatory analysis reveals that T-bet controls Th17 lineage differentiation through direct suppression of IRF4.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b056ebd525a3f82e22b1c43010afc913"><gtr:id>b056ebd525a3f82e22b1c43010afc913</gtr:id><gtr:otherNames>G?kmen MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1E472EFF-0790-4B87-8858-A8766ABFA626"><gtr:id>1E472EFF-0790-4B87-8858-A8766ABFA626</gtr:id><gtr:title>T-cell alloimmunity and chronic allograft dysfunction.</gtr:title><gtr:parentPublicationTitle>Kidney international. Supplement</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f8f79b3b082d0af0f2cd8470d59b7efb"><gtr:id>f8f79b3b082d0af0f2cd8470d59b7efb</gtr:id><gtr:otherNames>Safinia N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0098-6577</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/642B9F3D-22AB-40E9-A800-5A0B72B115E5"><gtr:id>642B9F3D-22AB-40E9-A800-5A0B72B115E5</gtr:id><gtr:title>Increased CD40 Ligation and Reduced BCR Signalling Leads to Higher IL-10 Production in B Cells From Tolerant Kidney Transplant Patients.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4a852e087195ad0146102a9de3e4ab8b"><gtr:id>4a852e087195ad0146102a9de3e4ab8b</gtr:id><gtr:otherNames>Nova-Lamperti E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/394476EC-64BA-4EB6-B5C6-D05FC3CCFA67"><gtr:id>394476EC-64BA-4EB6-B5C6-D05FC3CCFA67</gtr:id><gtr:title>Cell therapy to promote transplantation tolerance: a winning strategy?</gtr:title><gtr:parentPublicationTitle>Immunotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1cc75691dbb514909ad66036a04b718e"><gtr:id>1cc75691dbb514909ad66036a04b718e</gtr:id><gtr:otherNames>Lombardi G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1750-743X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5C5F3995-D7D3-4727-8833-55FF5D4AC906"><gtr:id>5C5F3995-D7D3-4727-8833-55FF5D4AC906</gtr:id><gtr:title>IL-10-produced by human transitional B-cells down-regulates CD86 expression on B-cells leading to inhibition of CD4+T-cell responses.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4a852e087195ad0146102a9de3e4ab8b"><gtr:id>4a852e087195ad0146102a9de3e4ab8b</gtr:id><gtr:otherNames>Nova-Lamperti E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E8346F08-FB75-4FF1-B69C-CBBBD35AEE95"><gtr:id>E8346F08-FB75-4FF1-B69C-CBBBD35AEE95</gtr:id><gtr:title>A common gene signature across multiple studies relate biomarkers and functional regulation in tolerance to renal allograft.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/defaa18a89e21eb999004914461c74ef"><gtr:id>defaa18a89e21eb999004914461c74ef</gtr:id><gtr:otherNames>Baron D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801537</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>2EEE0958-6BE1-4D16-B86B-5D954CD37219</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Renal and Urogenital</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>